Abstract

BackgroundFew studies investigated the concordance in hypertension status and antihypertensive treatment recommendations between the 2018 Chinese Hypertension League (CHL) guidelines and the 2017 American College of Cardiology (ACC)/American Heart Association (AHA) guidelines and assessed the change of premature mortality risk with hypertension defined by the ACC/AHA guidelines.MethodsWe used the baseline data of the China Health and Retirement Longitudinal Study (CHARLS) to estimate the population impact on hypertension management between CHL and ACC/AHA guidelines. Mortality risk from hypertension was estimated using the data from China Health and Nutrition Survey (CHNS). Cox proportional hazards model was used to estimate the hazard ratios (HRs) and their 95% confidence intervals(CIs).ResultsAmong 13,704 participants analyzed from the nationally representative data of CHARLS, 42.64% (95% CI: 40.35, 44.96) of Chinese adults were diagnosed by both CHL and ACC/AHA guidelines. 41.25% (39.17, 43.36) did not have hypertension according to either guideline. Overall, the concordance in hypertension status was 83.89% (81.69, 85.57). A high percentage of agreement was also found for recommendation to initiate treatment among untreated subjects (87.62% [86.67, 88.51]) and blood pressure (BP) above the goal among treated subjects (71.68% [68.16, 74.95]). Among 23,063 adults from CHNS, subjects with hypertension by CHL had a higher risk of premature mortality (1.75 [1.50, 2.04]) compared with those without hypertension. The association diminished for hypertension by ACC/AHA (1.46 [1.07, 1.30]). Moreover, the excess risk was not significant for the newly defined Grade 1 hypertension by ACC/AHA (1.15 [0.95, 1.38]) when compared with BP <120/80 mmHg. This contrasted with the estimate from CHL (1.54 [1.25, 1.89]). The same pattern was observed for total mortality.ConclusionsIf ACC/AHA guidelines were adopted, a high degree of concordance in hypertension status and initiation of antihypertensive treatment was found with CHL guidelines. However, the mortality risk with hypertension was reduced with a non-significant risk for Grade 1 hypertension defined by the ACC/AHA.

Highlights

  • In 2017, the American College of Cardiology/American Heart Association (ACC/AHA) released an updated blood pressure (BP) guidelines and reduced the diagnostic threshold for hypertension to systolic blood pressure (SBP)/diastolic blood pressure (DBP) ≥130/80 mmHg [1]

  • To further explore the mortality risk of different subgroups of hypertension defined by ACC/AHA and Chinese Hypertension League (CHL) guidelines, we analyzed the data from China Health and Nutrition Survey (CHNS)

  • Percentage and Number of Hypertension, Recommended Initiating Antihypertensive Medication, Above-The-Goal BP Defined by Chinese and ACC/AHA Guidelines

Read more

Summary

Introduction

In 2017, the American College of Cardiology/American Heart Association (ACC/AHA) released an updated blood pressure (BP) guidelines and reduced the diagnostic threshold for hypertension to systolic blood pressure (SBP)/diastolic blood pressure (DBP) ≥130/80 mmHg [1] This contrasts with the 2018 Chinese Hypertension League (CHL) BP guidelines and the 2018 European Society of Cardiology (ESC)/European Society of Hypertension (ESH) BP guidelines, where hypertension is diagnosed based on a threshold of ≥140/90 mmHg [2, 3]. Few studies investigated the concordance in hypertension status and antihypertensive treatment recommendations between the 2018 Chinese Hypertension League (CHL) guidelines and the 2017 American College of Cardiology (ACC)/American Heart Association (AHA) guidelines and assessed the change of premature mortality risk with hypertension defined by the ACC/AHA guidelines

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call